Lead Story
Isar Aerospace's Spectrum becomes first privately built rocket to reach orbit from Western European soil
The German company Isar Aerospace successfully launched its Spectrum rocket from Andøya Spaceport in northern Norway on Saturday, September 5, 2026, reaching orbit roughly seven minutes after liftoff and deploying five satellites, in what was described as the first orbital launch of a payload from Western European territory and the first fully commercial European launch vehicle to reach orbit. The two-stage rocket, built to carry up to 1,000 kilograms to low Earth orbit, marked a comeback for the company after an earlier test flight from the same site crashed seconds after launch in March 2025. Chief engineer Nikolaos Perakis called the milestone a moment of 'making history... for Europe,' underscoring the continent's push to build independent commercial access to space.
Read more →Lead Story
Isar Aerospace's Spectrum becomes first privately built rocket to reach orbit from Western European soil
The German company Isar Aerospace successfully launched its Spectrum rocket from Andøya Spaceport in northern Norway on Saturday, September 5, 2026, reaching orbit roughly seven minutes after liftoff and deploying five satellites, in what was described as the first orbital launch of a payload from Western European territory and the first fully commercial European launch vehicle to reach orbit. The two-stage rocket, built to carry up to 1,000 kilograms to low Earth orbit, marked a comeback for the company after an earlier test flight from the same site crashed seconds after launch in March 2025. Chief engineer Nikolaos Perakis called the milestone a moment of 'making history... for Europe,' underscoring the continent's push to build independent commercial access to space.
Large real-world study finds Ozempic and Wegovy linked to nearly 40% fewer asthma attacks
A study presented at the European Respiratory Society Congress in Barcelona this week found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups among patients who started the GLP-1 medication, compared with those on other diabetes treatments. Led by Chloe Bloom of Imperial College London's National Heart & Lung Institute, the research drew on real-world health records across four parallel studies of 20,000 to 22,000 people each. Researchers say the findings suggest GLP-1 drugs may offer respiratory benefits beyond their known effects on diabetes and obesity, though they caution that clinical trials are still needed to confirm the results.
Read more →Large real-world study finds Ozempic and Wegovy linked to nearly 40% fewer asthma attacks
A study presented at the European Respiratory Society Congress in Barcelona this week found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups among patients who started the GLP-1 medication, compared with those on other diabetes treatments. Led by Chloe Bloom of Imperial College London's National Heart & Lung Institute, the research drew on real-world health records across four parallel studies of 20,000 to 22,000 people each. Researchers say the findings suggest GLP-1 drugs may offer respiratory benefits beyond their known effects on diabetes and obesity, though they caution that clinical trials are still needed to confirm the results.
Scientists identify a bone-building molecular switch that could help reverse osteoporosis
Researchers reported this week that activating a receptor called GPR133 (also known as ADGRD1) triggers bone-forming cells to build new bone while slowing down the cells that break it down, using an experimental compound, AP503, identified through a computer-assisted screen. In lab tests, AP503 significantly increased bone strength in both healthy and osteoporotic mice, and the same pathway has also been linked to stronger muscles, giving researchers hope for treatments targeting age-related bone and muscle decline. The findings point to a promising new therapeutic avenue for osteoporosis, a condition that weakens bones in millions of older adults worldwide.
Read more →Scientists identify a bone-building molecular switch that could help reverse osteoporosis
Researchers reported this week that activating a receptor called GPR133 (also known as ADGRD1) triggers bone-forming cells to build new bone while slowing down the cells that break it down, using an experimental compound, AP503, identified through a computer-assisted screen. In lab tests, AP503 significantly increased bone strength in both healthy and osteoporotic mice, and the same pathway has also been linked to stronger muscles, giving researchers hope for treatments targeting age-related bone and muscle decline. The findings point to a promising new therapeutic avenue for osteoporosis, a condition that weakens bones in millions of older adults worldwide.
FDA authorizes first standalone robot that can draw blood without a phlebotomist's hands-on help
The US Food and Drug Administration granted De Novo authorization to Aletta, a robotic blood-draw device made by Dutch startup Vitestro, clearing it for use on adults in outpatient settings under the oversight of a trained phlebotomist supervisor who can watch over up to three devices at once. Aletta uses near-infrared light and Doppler ultrasound to locate a vein, then automates the tourniquet, needle insertion and disposal, and bandaging steps of a blood draw; the FDA said adverse events during testing were infrequent and mild. The device, already in use at hospitals and laboratories in Europe as part of a clinical trial, could help ease a persistent phlebotomist shortage in the United States.
Read more →FDA authorizes first standalone robot that can draw blood without a phlebotomist's hands-on help
The US Food and Drug Administration granted De Novo authorization to Aletta, a robotic blood-draw device made by Dutch startup Vitestro, clearing it for use on adults in outpatient settings under the oversight of a trained phlebotomist supervisor who can watch over up to three devices at once. Aletta uses near-infrared light and Doppler ultrasound to locate a vein, then automates the tourniquet, needle insertion and disposal, and bandaging steps of a blood draw; the FDA said adverse events during testing were infrequent and mild. The device, already in use at hospitals and laboratories in Europe as part of a clinical trial, could help ease a persistent phlebotomist shortage in the United States.
North Atlantic right whales post best calving season since 2009, with 23 new calves
The 2026 North Atlantic right whale calving season produced 23 mother-calf pairs off the southeastern United States, the highest count since 2009, according to results confirmed this season by NOAA Fisheries and the New England Aquarium. Twenty of the 23 mothers were returning moms, and thirteen of them had shorter-than-average gaps since their last calves — well under the recent average interval of 7 to 10 years — a sign researchers see as cautiously encouraging for the critically endangered species, which numbers only a few hundred individuals. Scientists caution the population still faces serious threats from ship strikes and fishing gear entanglement, but say the birth numbers suggest recovery efforts may be starting to pay off.
Read more →North Atlantic right whales post best calving season since 2009, with 23 new calves
The 2026 North Atlantic right whale calving season produced 23 mother-calf pairs off the southeastern United States, the highest count since 2009, according to results confirmed this season by NOAA Fisheries and the New England Aquarium. Twenty of the 23 mothers were returning moms, and thirteen of them had shorter-than-average gaps since their last calves — well under the recent average interval of 7 to 10 years — a sign researchers see as cautiously encouraging for the critically endangered species, which numbers only a few hundred individuals. Scientists caution the population still faces serious threats from ship strikes and fishing gear entanglement, but say the birth numbers suggest recovery efforts may be starting to pay off.